| Q46270646 | A 3.0-Angstrom Resolution Cryo-Electron Microscopy Structure and Antigenic Sites of Coxsackievirus A6-Like Particles |
| Q38831138 | A bivalent virus-like particle based vaccine induces a balanced antibody response against both enterovirus 71 and norovirus in mice |
| Q36363771 | A neonatal mouse model of coxsackievirus A16 for vaccine evaluation |
| Q46147430 | A new factor influencing pathogen detection by molecular assay in children with both mild and severe hand, foot, and mouth disease |
| Q40378849 | A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice. |
| Q33685512 | A novel universal neutralizing monoclonal antibody against enterovirus 71 that targets the highly conserved "knob" region of VP3 protein |
| Q33621078 | A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge |
| Q46825689 | A safety study of inactivated Enterovirus 71 vaccine |
| Q42211021 | A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice |
| Q47237112 | A virus-like particle vaccine confers protection against enterovirus D68 lethal challenge in mice |
| Q45354931 | A virus-like particle vaccine for coxsackievirus A16 potently elicits neutralizing antibodies that protect mice against lethal challenge |
| Q55099892 | A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity. |
| Q39240063 | Adoptive transfer of macrophages from adult mice reduces mortality in mice infected with human enterovirus 71. |
| Q92968336 | An inactivated enterovirus 71 vaccine is safe and immunogenic in healthy adults: A phase I, double blind, randomized, placebo-controlled, study of two dosages |
| Q84129185 | Analysis of the Th1/Th2 reaction in the immune response induced by EV71 inactivated vaccine in neonatal rhesus monkeys |
| Q38833043 | Antibodies to P-selectin glycoprotein ligand-1 block dendritic cell-mediated enterovirus 71 transmission and prevent virus-induced cells death. |
| Q39255114 | Antigenic analysis of divergent genotypes human Enterovirus 71 viruses by a panel of neutralizing monoclonal antibodies: current genotyping of EV71 does not reflect their antigenicity. |
| Q88883557 | Antivirals and vaccines for Enterovirus A71 |
| Q38172045 | Bioengineering virus-like particles as vaccines |
| Q35689929 | Broad protection with an inactivated vaccine against primary-isolated lethal enterovirus 71 infection in newborn mice |
| Q40113232 | Characterization of human enterovirus71 virus-like particles used for vaccine antigens. |
| Q36978457 | Characterization of the enterovirus 71 P1 polyprotein expressed in Pichia pastor as a candidate vaccine |
| Q38832137 | Characterizing Enterovirus 71 and Coxsackievirus A16 virus-like particles production in insect cells. |
| Q37547757 | Chimeric virus-like particle vaccines displaying conserved enterovirus 71 epitopes elicit protective neutralizing antibodies in mice through divergent mechanisms |
| Q43934303 | Combined peptides of human enterovirus 71 protect against virus infection in mice |
| Q34430681 | Comparative analysis of the immunogenicity and protective effects of inactivated EV71 vaccines in mice |
| Q33887710 | Cryo-electron microscopy study of insect cell-expressed enterovirus 71 and coxsackievirus a16 virus-like particles provides a structural basis for vaccine development |
| Q40889243 | Determinants of EV71 immunogenicity and protection against lethal challenge in a mouse model |
| Q34765645 | Development and evaluation of a pseudovirus-luciferase assay for rapid and quantitative detection of neutralizing antibodies against enterovirus 71. |
| Q38879324 | Development of EV71 virus-like particle purification processes |
| Q38195326 | Development of enterovirus 71 vaccines: from the lab bench to Phase III clinical trials |
| Q38618258 | Different applications of virus-like particles in biology and medicine: Vaccination and delivery systems |
| Q33958090 | Display of VP1 on the surface of baculovirus and its immunogenicity against heterologous human enterovirus 71 strains in mice |
| Q84446181 | Display of enterovirus 71 VP1 on baculovirus as a type II transmembrane protein elicits protective B and T cell responses in immunized mice |
| Q28076658 | EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases |
| Q41153130 | EV71 infection correlates with viral IgG preexisting at pharyngo-laryngeal mucosa in children |
| Q36496385 | EV71 virus-like particles produced by co-expression of capsid proteins in yeast cells elicit humoral protective response against EV71 lethal challenge |
| Q37715371 | EV71: an emerging infectious disease vaccine target in the Far East? |
| Q64123371 | Efficient expression of enterovirus 71 based on virus-like particles vaccine |
| Q41209873 | Enhanced enterovirus 71 virus-like particle yield from a new baculovirus design |
| Q57049727 | Enhanced neutralizing antibody response induced by inactivated enterovirus 71 in cynomolgus monkeys |
| Q89782338 | Enterovirus 71 Infection Shapes Host T Cell Receptor Repertoire and Presumably Expands VP1-Specific TCRβ CDR3 Cluster |
| Q30238518 | Enterovirus 71 infection and vaccines |
| Q33558268 | Enterovirus 71 vaccine: close but still far. |
| Q39662972 | Enterovirus 71 virus-like particle vaccine: Improved production conditions for enhanced yield |
| Q34532705 | Enterovirus 71-induced neurological disorders in young gerbils, Meriones unguiculatus: development and application of a neurological disease model |
| Q38840182 | Enterovirus 71: a whole virion inactivated enterovirus 71 vaccine |
| Q60922605 | Enterovirus A71 Infection and Neurologic Disease, Madrid, Spain, 2016 |
| Q47555463 | Enterovirus D68 virus-like particles expressed in Pichia pastoris potently induce neutralizing antibody responses and confer protection against lethal viral infection in mice |
| Q34697319 | Enterovirus infections of the central nervous system |
| Q44079611 | Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles. |
| Q34435050 | Enterovirus-71 virus-like particles induce the activation and maturation of human monocyte-derived dendritic cells through TLR4 signaling |
| Q38845816 | Enterovirus71 virus-like particles produced from insect cells and purified by multistep chromatography elicit strong humoral immune responses in mice |
| Q36571245 | Enteroviruses in the early 21st century: new manifestations and challenges |
| Q57096715 | Establishing China's national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines |
| Q41723927 | Establishment of a panel of in-house polyclonal antibodies for the diagnosis of enterovirus infections |
| Q33723474 | Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice |
| Q84815049 | Expression and purification of enterovirus type 71 polyprotein P1 using Pichia pastoris system |
| Q35625893 | Expression of enterovirus 71 virus-like particles in transgenic enoki (Flammulina velutipes). |
| Q83399098 | Formaldehyde-inactivated human enterovirus 71 vaccine is compatible for co-immunization with a commercial pentavalent vaccine |
| Q41988715 | Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease |
| Q84059759 | Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection |
| Q24337770 | Heat shock protein 90: role in enterovirus 71 entry and assembly and potential target for therapy |
| Q45324939 | Hepatitis B virus core particles containing multiple epitopes confer protection against enterovirus 71 and coxsackievirus A16 infection in mice |
| Q41373115 | High-yield production of recombinant virus-like particles of enterovirus 71 in Pichia pastoris and their protective efficacy against oral viral challenge in mice |
| Q28478931 | Human SCARB2-mediated entry and endocytosis of EV71 |
| Q37670343 | Human enterovirus 71 and hand, foot and mouth disease. |
| Q39556922 | Identification and characterization of a cross-neutralization epitope of Enterovirus 71. |
| Q33643774 | Immunization of N terminus of enterovirus 71 VP4 elicits cross-protective antibody responses. |
| Q93160260 | Immunization with a fusion protein vaccine candidate generated from truncated peptides of human enterovirus 71 protects mice from lethal enterovirus 71 infections |
| Q38843917 | Immunogenicity and performance of an enterovirus 71 virus-like-particle vaccine in nonhuman primates |
| Q36256455 | Immunogenicity and protective efficacy of an EV71 virus-like particle vaccine against lethal challenge in newborn mice |
| Q45197531 | Immunogenicity and protective efficacy of virosome based vaccines against Newcastle disease |
| Q28743371 | Immunogenicity and safety of virus-like particle of the porcine encephalomyocarditis virus in pig |
| Q28485432 | Immunological and biochemical characterization of coxsackie virus A16 viral particles |
| Q36248450 | Immunological evaluation and comparison of different EV71 vaccine candidates |
| Q47145137 | Immunopathogenesis and Virus-Host Interactions of Enterovirus 71 in Patients with Hand, Foot and Mouth Disease |
| Q46801574 | Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys |
| Q30234918 | Impact of genetic changes, pathogenicity and antigenicity on Enterovirus- A71 vaccine development |
| Q54247724 | Induction of a high-titered antibody response using HIV gag-EV71 VP1-based virus-like particles with the capacity to protect newborn mice challenged with a lethal dose of enterovirus 71. |
| Q37909427 | Insect cell technology is a versatile and robust vaccine manufacturing platform |
| Q91677805 | Insights into innate and adaptive immune responses in vaccine development against EV-A71 |
| Q35005059 | MEK/ERK signaling pathway is required for enterovirus 71 replication in immature dendritic cells |
| Q34603692 | Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre- and post-attachment steps |
| Q57187881 | Non-clinical safety assessment of repeated intramuscular administration of an EV-A71 VLP vaccine in rabbits |
| Q40353511 | Nucleocapsid-like particles of dengue-2 virus enhance the immune response against a recombinant protein of dengue-4 virus. |
| Q42280748 | Oral immunization of mice using Bifidobacterium longum expressing VP1 protein from enterovirus 71. |
| Q33619912 | Oral immunization with recombinant enterovirus 71 VP1 formulated with chitosan protects mice against lethal challenge |
| Q43167772 | Overlapping CD8+ and CD4+ T-cell epitopes identification for the progression of epitope-based peptide vaccine from nucleocapsid and glycoprotein of emerging Rift Valley fever virus using immunoinformatics approach. |
| Q45364181 | Partial protection against enterovirus 71 (EV71) infection in a mouse model immunized with recombinant Newcastle disease virus capsids displaying the EV71 VP1 fragment |
| Q51534139 | Pathogen-Mimicking Polymeric Nanoparticles based on Dopamine Polymerization as Vaccines Adjuvants Induce Robust Humoral and Cellular Immune Responses. |
| Q31056961 | Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates |
| Q91726510 | Plant-Produced Anti-Enterovirus 71 (EV71) Monoclonal Antibody Efficiently Protects Mice Against EV71 Infection |
| Q42254889 | Preclinical evaluation of the immunogenicity and safety of an inactivated enterovirus 71 candidate vaccine |
| Q26866091 | Production of EV71 vaccine candidates |
| Q38068107 | Progress on the research and development of human enterovirus 71 (EV71) vaccines |
| Q37530094 | Progress on the research and development of inactivated EV71 whole-virus vaccines |
| Q34358402 | Protection against enterovirus 71 with neutralizing epitope incorporation within adenovirus type 3 hexon |
| Q33908518 | Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system. |
| Q33646488 | Recombinant tandem multi-linear neutralizing epitopes of human enterovirus 71 elicited protective immunity in mice |
| Q33590806 | Rupintrivir is a promising candidate for treating severe cases of Enterovirus-71 infection |
| Q99240705 | SARS-CoV-2 vaccine research and development: conventional vaccines and biomimetic nanotechnology strategies |
| Q34497860 | Serum inflammatory cytokine levels correlate with hand-foot-mouth disease severity: a nested serial case-control study |
| Q33812653 | Subviral particle as vaccine and vaccine platform |
| Q41504927 | Systemic antibody response to nano-size calcium phospate biocompatible adjuvant adsorbed HEV-71 killed vaccine. |
| Q28066400 | The Current Status of the Disease Caused by Enterovirus 71 Infections: Epidemiology, Pathogenesis, Molecular Epidemiology, and Vaccine Development |
| Q84230593 | The Pathogenesis and Prevention of Encephalitis due to Human Enterovirus 71 |
| Q38603912 | The application of virus-like particles as vaccines and biological vehicles |
| Q33732200 | The cross-reactivity of the enterovirus 71 to human brain tissue and identification of the cross-reactivity related fragments |
| Q37886179 | The virology and developments toward control of human enterovirus 71. |
| Q38567118 | Understanding Enterovirus 71 Neuropathogenesis and Its Impact on Other Neurotropic Enteroviruses |
| Q38243160 | Update on baculovirus as an expression and/or delivery vehicle for vaccine antigens |
| Q38225695 | Update on the development of enterovirus 71 vaccines |
| Q42014293 | Vaccination with coxsackievirus B3 virus-like particles elicits humoral immune response and protects mice against myocarditis |
| Q40627065 | Vesicular stomatitis virus-based vaccines expressing EV71 virus-like particles elicit strong immune responses and protect newborn mice from lethal challenges |
| Q37996089 | Viral and host factors that contribute to pathogenicity of enterovirus 71. |
| Q37801742 | Virology, epidemiology, pathogenesis, and control of enterovirus 71. |
| Q37282912 | Virus-Like Particles Produced in Pichia Pastoris Induce Protective Immune Responses Against Coxsackievirus A16 in Mice. |
| Q40638141 | Virus-like particle-based vaccine against coxsackievirus A6 protects mice against lethal infections. |
| Q44201038 | Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. |
| Q38197494 | Virus-like particles in picornavirus vaccine development |
| Q42265420 | Virus-like particles produced in Saccharomyces cerevisiae elicit protective immunity against Coxsackievirus A16 in mice |